KemPharm (NASDAQ:KMPH) was upgraded by investment analysts at ValuEngine from a “strong sell” rating to a “sell” rating in a report released on Sunday.
A number of other equities analysts also recently commented on KMPH. Canaccord Genuity reissued a “buy” rating and issued a $7.00 target price on shares of KemPharm in a research note on Monday, September 11th. Zacks Investment Research downgraded shares of KemPharm from a “buy” rating to a “hold” rating in a research note on Thursday, November 16th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average price target of $8.05.
KemPharm (NASDAQ:KMPH) opened at $4.05 on Friday. KemPharm has a one year low of $2.45 and a one year high of $5.40. The company has a quick ratio of 7.56, a current ratio of 7.56 and a debt-to-equity ratio of -1.92. The company has a market cap of $59.36, a price-to-earnings ratio of -1.53 and a beta of -1.10.
An institutional investor recently raised its position in KemPharm stock. Alyeska Investment Group L.P. boosted its position in shares of KemPharm, Inc. (NASDAQ:KMPH) by 1.8% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 992,338 shares of the specialty pharmaceutical company’s stock after purchasing an additional 17,721 shares during the period. Alyeska Investment Group L.P. owned approximately 6.77% of KemPharm worth $3,672,000 at the end of the most recent reporting period. 36.04% of the stock is owned by hedge funds and other institutional investors.
WARNING: “KemPharm (KMPH) Upgraded to “Sell” by ValuEngine” was first posted by Chaffey Breeze and is owned by of Chaffey Breeze. If you are accessing this piece on another site, it was copied illegally and republished in violation of US and international copyright and trademark laws. The legal version of this piece can be accessed at https://www.chaffeybreeze.com/2018/01/01/kempharm-kmph-upgraded-to-sell-by-valuengine.html.
KemPharm Company Profile
KemPharm, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in the discovery and development of prodrugs. The Company uses its Ligand Activated Therapy (LAT) platform technology to create prodrugs. The Company’s product candidate, KP201/APAP, consists of KP201, its prodrug of hydrocodone, which is combined with acetaminophen (APAP).
Receive News & Ratings for KemPharm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KemPharm and related companies with MarketBeat.com's FREE daily email newsletter.